Carboplatin is used in many kind of tumors with similar results to cisplatin but without the same toxicity. We decided to use it, in combination with etoposide, for metastatic breast cancer. Eighteen women with advanced breast disease entered this phase II study. Each of them received, every 28 days, carboplatin on day 1, at a dose calculated with the Calvert formula, and etoposide on days 1, 2, 3 at a dose of 100 mg/m2. For 12 women this treatment was the first-line chemotherapy, while for the other six it was the second-line therapy, after the administration and the failure, in 4 cases out of 6, of regimens based on anthracycline. In each group we obtained an objective response of 50%, with a complete response of 25% in the first and of 33% in the second. On the whole, 11 patients died (one not from the disease) (10/18, 55%). Toxicity was extremely mild, with only one patient with grade III anemia. Our data suggest that a carboplatin/etoposide combination could be active and well-tolerated in patients with metastatic breast cancer, but the few number of patients in this study makes further research necessary for confirmation.

Carboplatin

Regimen

Source

Cite

Citations (6)

Cost/Accuracy Ratio Analysis in Breast Cancer Patients Undergoing Ultrasound‐Guided Fine‐Needle Aspiration Cytology, Sentinel Node Biopsy, and Frozen Section of Node

World Journal of Surgery (2007)

Franco Tarro Genta E Zanon Marco Camanni Francesco Deltetto Mauro Drogo

Cardiothoracic surgery

Vascular surgery

10.1007/s00268-007-9009-3

Cite

Citations (66)

Laparoscopic stripping of endometriomas negatively affects ovarian follicular reserve even if performed by experienced surgeons

Reproductive BioMedicine Online (2011)

Chiara Perono Biacchiardi Luisa Delle Piane Marco Camanni Francesco Deltetto Elena Maria Delpiano

Ovarian Reserve

Antral follicle

Anti-Müllerian hormone

10.1016/j.rbmo.2011.07.014

Cite

Citations (147)

Is it possible to obtain a presurgical Lasmar score for hysteroscopic myomectomy by ultrasound alone?

Ultrasound in Obstetrics and Gynecology (2012)

Marco Camanni Luca Bonino M. Tessarolo Giuseppe Migliaretti Bruno Ferrero

To determine whether a Lasmar score obtained entirely by the use of two-dimensional (2D) and three-dimensional (3D) ultrasound provides results similar to those obtained using the original hysteroscopic technique.This was a prospective study performed on a series of patients presenting with symptomatic submucous fibroids and scheduled for hysteroscopic myomectomy. Ultrasound Lasmar scores were obtained by a single physician, a specialist in ultrasonography, in the luteal phase of the menstrual cycle. 3D images were evaluated by offline examination using multiplanar analysis. Classical Lasmar scores were obtained by a different physician, a specialist in hysteroscopy, during the follicular phase of the subsequent cycle. Surgery was performed by a third physician in the follicular phase who also reported a Lasmar score, which we considered as the gold standard. The concordance between group classifications (I-III, relating to difficulty of hysteroscopic resection) according to the three methods used to obtain the Lasmar score (ultrasound, classical and surgery) was calculated using Cohen's κ statistic.Thirty-four women, with a mean age of 43 ± 4.9 years, were enrolled in the study. Thirty-six submucous fibroids were identified by both ultrasound and diagnostic hysteroscopy. The mean diameter of fibroids evaluated was 28 ± 13.2 mm. The concordance between the three methods of classifying patients according to Lasmar score was high: classical vs. surgery, κ = 0.88; ultrasound vs. surgery, κ = 0.93; and classical vs. ultrasound, κ = 0.77.The Lasmar score can be obtained solely by ultrasound examination performed in the luteal phase of the menstrual cycle, avoiding office hysteroscopy without a loss of diagnostic accuracy.

Concordance

Gold standard (test)

10.1002/uog.11165

Cite

Citations (8)

Where Morphological and Molecular Classifications Meet: The Role of p53 Immunohistochemistry in the Prognosis of Low-Risk Endometrial Carcinoma (GLAMOUR Study)

Cancers (2024)

Andrea Puppo Giulio Fraternali Orcioni Valentino Clignon Yuri Musizzano Carla Angela Zavattero

No prospective study has validated molecular classification to guide adjuvant treatment in endometrial cancer (EC), and not even retrospective data are present for patients with morphological low-risk EC. We conducted a retrospective, multicenter, observational study including 370 patients with low-risk endometrioid EC to evaluate the incidence and prognostic role of p53 abnormal expression (p53abn) in this specific subgroup. Among 370 patients, 18 had abnormal expressions of p53 (4.9%). In 13 out of 370 patients (3.6%), recurrences were observed and two were p53abn. When adjusting for median follow-up time, the odds ratio (OR) for recurrence among those with p53abn versus p53 wild type (p53wt) was 5.23—CI 95% 0.98–27.95, p = 0.053. The most common site of recurrence was the vaginal cuff (46.2%). One recurrence occurred within the first year of follow-up, and the patient exhibited p53abn. Both 1-year and 2-year DFS rates were 94.4% and 100% in the p53abn and p53wt groups, respectively. One patient died from the disease and comprised p53wt. No difference in OS was registered between the two groups; the median OS was 21.9 months (16.4–30.1). Larger multicenter studies are needed to tailor the treatment of low-risk EC patients with p53abn. Performing molecular classification on all EC patients might be cost-effective, and despite the limits of our relatively small sample, p53abn patients seem to be at greater risk of recurrence, especially locally and after two years since diagnosis.

10.3390/cancers16061088

Cite

Citations (2)